Business Context and Reporting Period
Company: Amphastar Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2016
Reporting Period: Three months ended June 30, 2016
This filing serves as a notification that the company issued a press release announcing its financial results for the second quarter of 2016. The detailed financial data is contained within the attached press release (Exhibit 99.1) and is not embedded directly in the text of this 8-K form.
Key Financial Metrics
The text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the press release furnished as Exhibit 99.1.
Material Changes
No material changes or comparative financial data are disclosed within the body of this filing. The document solely references the issuance of the quarterly results announcement.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that management has released results for the period ended June 30, 2016, but does not summarize specific commentary, guidance, or outlook within this text.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing. The document includes a standard disclaimer stating that the information in the press release (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 8, 2016) for actual revenue, net income, and EPS figures.
- Verify year-over-year and quarter-over-quarter growth rates in the attached press release.
- Check for any forward-looking statements or guidance updates in the press release text.
- Confirm the status of the company's cash position and debt levels as reported in the full quarterly results.